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Parvovirus B19 (PVB19) is a nonenveloped DNAviruswhich is
a ubiquitous human pathogen, primarily spread via respira-
tory droplets. The infection can be symptomatic or asymp-
tomatic according to the host’s age and immunologic status.
The natural course of the infection in immunosuppressed
individuals such as renal transplant recipients (RTR) are
varied.1 Although anemia is the most common manifesta-
tion,2 PVB19 can also cause pancytopenia, hepatitis, myocar-
ditis, neurological disease,1,3,4 and allograft dysfunction.5
Transmission can occur to the recipient from the allograft
itself, as the virus may persist for years in seropositive









Abstract Parvovirus B19 (PVB19) is a DNA virus which causes clinically relevant infection in renal
transplant recipients (RTR) leading to signiﬁcant morbidity. Manifestations include
erythropoietin resistant anemia, proteinuria, and glomerulosclerosis in the allograft.
Severe infection may require administration of intravenous immunoglobulin, reduction
in immunosuppression and transfusions. The major challenge in managing and
preventing the infection in RTR involves the act of balancing the decreased level of
immunosuppression and the risk of rejection. The objective of this article is to
understand the importance of PVB19 infection and its outcome in RTR. We reviewed
the medical records of three RTR with conﬁrmed PVB19 infection and recorded patient
information including demographics, clinical and laboratory data, management, and
outcome. The average time of occurrence of PVB19 infection as transplant was 8.6
weeks and they presented with symptomatic anemia. Elevated creatinine values were
noted in two of them. Following treatment, anemia improved and creatinine values
returned to baseline. One of them developed an early relapse and had to be treated once
again similarly. We emphasize the importance of maintaining a high index of suspicion
for PVB19 infection in patients with anemia in the posttransplant phase, especially in
patients on higher doses of immunosuppressants. Early and proper treatment can
prevent worsening clinical condition and possible effects on the allograft.
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donors for PVB19 and monitor for possible manifestations
such as resistant anemia in RTR. The major challenge in
managing and preventing PVB19 infection in RTR involves
the act of balancing the decreased level of immunosuppres-
sion and the risk of rejection.
Patients and Methods
We retrospectively reviewed the medical records of 144 RTR
who were followed up at a tertiary care hospital afﬁliated
transplant program from January 2007 to June 2013 and
selected three patients with conﬁrmed PVB19 infection. The
maintenance immunosuppression protocol that was followed
consisted of tacrolimus, mycophenolate mofetil, and predni-
sone. These patients presented with anemia in the posttrans-
plant period, and were subsequently diagnosed with PVB19
infection. We collected patient information including demo-
graphics, clinical, and laboratory data. The detection of
infection was done by polymerase chain reaction (PCR) or
immunoglobulin M (IgM) serology of blood samples or bone
marrow study indicative of PVB19. The management and
outcome was also recorded. The study has been approved by
the Institutional Review Board at the hospital.
Results
Of 144 RTR, there were 3 cases (2%) of PVB19 infection. All
recipients had normal baseline creatinine posttransplant. The
average time for detection of PVB19 infection since transplant
was 8.6 weeks and they presentedwith symptomatic anemia.
The lowest hemoglobin (Hb) value noted was 6 mg/dL.
Epstein-Barr virus and cytomegalovirus were the associated
coinfections. Elevated creatinine values were noted in two of
them. Following treatment, anemia improved and creatinine
values returned to baseline. Sustained improvement in Hb
was seen after 4 weeks in two of them and after 12 weeks in
the third patient. One of them developed an episode of
recurrence.
Refer to ►Tables 1 to 3 for details regarding patient
characteristics, presentation and investigations, treatment
and outcome, respectively.
Refer to ►Fig. 1 for graph showing variations in Hb of the
three patients and ►Fig. 2 showing variations in creatinine
values of the three patients.
Discussion
RTR are highly susceptible to infections such as PVB197
because of the increased use of induction therapy to prevent
early acute rejection and because of the effect of sustained
long-term immunosuppression to prevent chronic rejection.
A study in 2006 identiﬁed that the median time for
occurrence of PVB19 infection after transplantation was
around 1.75 months, with majority of the cases occurring
within 3 months posttransplant.5
Chronic anemia is well-recognized complication in ap-
proximately 39% of RTR, with erythropoietin-resistant ane-
mia occurring in almost 9% of them.8 PVB19 is capable of
targeting erythroid progenitor cells in the bone marrow
leading to a cessation in erythropoiesis. This usually reverts
back to normal by the production of antibodies against the
virus in immunocompetent individuals. However in RTR, such
infections often lead to persistent pure red cell aplasia with
normal white cell and platelet counts.8 Studies suggest that
nearly 23% of RTR with persistent anemia had positive PCR
values for PVB19.8
Table 1 General information of the recipients and donors
Patient 1 Patient 2 Patient 3
Age (y) 58 44 30
Gender M F M
Comorbidities DM, HTN HTN HTN
Cause of ESRD DM, HTN Obstructive uropathy Chronic glomerulonephritis
Year of transplant 2013 2010 2008
Age of donor (y) 23 41 22
Type of donor Live Live Live
HLA mismatches 5/6 6/6 5/6
Induction protocol Basiliximab, steroid Basiliximab, steroid Basiliximab, steroid
Immunosuppression protocol Tacrolimus, MMF, prednisone Tacrolimus, MMF,
prednisone
Tacrolimus, MMF, prednisone
Acute rejection Acute cellular rejection at
2 weeks posttransplant, conﬁrmed
with biopsy, treated with pulse
IV Solumedrol
No No
Baseline creatinine (mg/dL) 1.3 1.12 1.2
Abbreviations: DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; HLA, human leukocyte antigen; HTN, hypertension; M, male; MMF,
mycophenolate mofetil.
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Immunosuppression is the major risk factor for the infec-
tion in RTR, indicated by improvement in anemia when
immunosuppression is decreased.9 Induction with antithy-
mocyte globulin is found to have a higher risk for the infection
comparedwith basiliximab.10 Substitution of tacrolimuswith
cyclosporine was also followed by viral clearance and resolu-
tion of anemia.9,11 Vigilance should be observed during high-
risk periods such as early after transplantation and after
treatment for rejection, when the dose of immunosuppres-
sants are high.4
Table 2 Parvovirus B19 infection presentation and investigations
Patient 1 Patient 2 Patient 3
Time of parvovirus
infection posttransplant
8 wk 7 wk 11 wk
Presentation Dizziness, dyspnea on exer-
tion, dark stools
Dizziness, dark stools Dizziness, dyspnea on exer-
tion, palpitation
Physical exam HR, 89; BP, 134/74; RR, 18;
Temp, 98, SpO2, 96%
HR, 100; BP, 130/54; RR, 18,
Temp, 98.6; SpO2, 98%
HR, 86; BP,110/68; RR,18;
Temp, 98.4; SpO2, 98%
Investigations: blood Hb, 6.6; Hct, 19.6; RBC count,
2.34; TC, 4,600; Plt, 295, RBC
indices, normal
Hb, 7.1; Hct, 21.2; RBC count,
2.31; TC, 6,300; Plt, 419; RBC
indices, normal
Hb, 6.3; Hct, 18.4; RBC count,
2.22; TC, 4,600; Plt, 320; RBC
indices, normal
Reticulocyte count, 0.3% Reticulocyte count, 0.2% Reticulocyte count, 0.2%
RBS, 230; Na, 140; K, 4.1; Cl,
106; HCO3, 21
RBS, 86; Na, 137; K,4.5; Cl,
105; HCO3, 20
RBS, 113; Na, 130; K,4.7; Cl,
100; HCO3, 21
BUN/Cr, 31/1.51 BUN/Cr, 20/1.27 BUN/Cr, 13/1.1
LDH, 134 LDH, 188 LDH, 144
Iron studies-increased iron and
ferritin, decreased TIBC
Iron studies-normal iron, in-
creased ferritin, decreased
TIBC
Iron studies-increased iron and
ferritin, decreased TIBC
Haptoglobin, normal; B12 and
folate, normal
Haptoglobin, normal; B12 and
folate, normal
Haptoglobin, normal; B12 and
folate, normal
Urinalysis, no proteinuria Urinalysis, no proteinuria Urinalysis, no proteinuria
Others FOB, negative FOB, positive Not indicated
CT abdomen-no evidence of
bleeding
CT abdomen-no evidence of
bleeding
CT abdomen-no evidence of
bleeding
OGD-erosive gastropathy OGD-normal Not indicated
Colonoscopy- normal Colonoscopy-pan colitis Not indicated
Initial management Aspirin stopped and patient
monitored for bleeding.
In spite of no active bleeding,
Hb continued to drop rapidly
and Parvovirus infection was
suspected
Treated conservatively for co-
litis, no further bleeding but
Hb continued to drop, BMA
done and showed erythroid
aplasia. Renal biopsy was done
due to rise in creatinine and it
showed hydropic changes in
tubular epithelial cells
Hb continued to drop, BMA
done which showed erythroid
aplasia.
Detection of parvovirus Positive PCR Bone marrow study, positive
PCR
Positive PCR, positive IgM se-
rology, bone marrow study
Co infections CMV PCR positive, EBV antigen
positive







Abbreviations: BP, blood pressure (mm Hg); BMA, bone marrow aspiration; BUN, blood urea nitrogen (mg/dL); Cl, chloride (mEq/L); CMV,
cytomegalovirus; Cr, creatinine (mg/dL); EBV, Epstein-Barr virus; FOB, fecal occult blood; Hb, hemoglobin (g/dL); HCO3, bicarbonate (mEq/L); Hct,
hematocrit (%); HR, heart rate (no of beats/min); K, potassium (mEq/L); LDH, lactate dehydrogenase (IU/L); Na, sodium (mEq/L); OGD,
esophagoduodenoscopy; PCR, polymerase chain reaction; Plt, platelet; RBS, random blood sugar (mg/dL); RBC, red blood cells; RR, respiratory rate
(per min); TC, total count; Temp, temperature (°F); TIBC, total iron binding capacity.
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Coinfection of PBV19 and other viruses such as cytomega-
lovirus and with human herpes virus 6 have also been
reported.12
Detection of PVB19 can be done via molecular techniques
or by measurement of viral antibodies. IgM assays will detect
a recent infection,13 but it is less reliable due to delayed or
inadequate humoral response.14 Viral DNA can be detected in
blood, bone marrow, and infected organs using PCR15 and is
also detected in asymptomatic individuals.16 However, the
detection of viral DNA with clinical ﬁndings is likely to
represent active infection. If serology and PCR are negative
but the clinical suspicion is high, examination of bone mar-
row specimen using immunohistochemical staining or in situ
hybridization is helpful in establishing the diagnosis.5
The main histopathological pictures of PVB19 infection of
allograft kidney are thromboticmicroangiopathyand collaps-
ing glomerulopathy.17–19 Reports have shown an elevation of
plasma creatinine and proteinuria.20
Table 3 Treatment and outcome of the patients
Patient 1 Patient 2 Patient 3









Hb posttreatment (g/dL) 12.1 13.1 11.5
Cr posttreatment (mg/dL) 1.19 1.15 1.3
Sustained Hb improvement After 4 wk After 4 wk After 12 wk
Recurrences No No Yes, one recurrence. treated
similarly
Allograft dysfunction Transient Transient No
Outcome Anemia resolved, no allo-
graft dysfunction, viral titers
decreased on follow-up, pa-
tient is still on routine im-
munosuppression protocol
because of his history of
acute rejection
Anemia resolved, no allo-
graft dysfunction, viral se-
rology became negative on
follow-up. Patient is on a
reduced dose of immuno-
suppression as the infection
Anemia resolved, no allo-
graft dysfunction, viral IgM
serology became negative.
Patient is on a reduced dose
of immunosuppression
since the infection
Abbreviations: Cr, creatinine; Hb, hemoglobin; IgM, immunoglobulin M; IVIG, intravenous immunoglobulin; PRBC, packed red blood cells.
Fig. 1 Graph showing variations in hemoglobin of the three patients.
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The treatmentof PBV19 is reductionof immunosuppression
and intravenous immunoglobulin (IVIG) administration.21 It is
also important to avoid the use of erythropoietin to combat the
anemiawhile treating PVB19, as this can lead to a resistance of
the virus to proven treatment.22
Conclusion
PVB19 is an important treatable cause of anemia in RTR. A
high indexof suspicion should bemaintained in patients with
anemia in the posttransplant phase, especially those who
have received higher doses of immunosuppressants. It maybe
relevant to screen-selected donors for asymptomatic PVB19
infection and to keep an eye out for anemia in RTR if the donor
has the infection. Further studies on a larger sample are
required to determinewhether recommendations for routine
donor screening need to be made. Early diagnosis and appro-
priate intervention can minimize the negative impacts of the
infection.
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